Last but not least, considering the lack of specific INSR inhibitor and the colitis-exacerbating effect of co-inhibitors, the development of insulin-specific inhibitors is urgently needed to study the INSR-targeted therapy for patients with IBD or other autoimmunity disease. This evidence concerns the gene INSR and colitis.